Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
Phase 3
Completed
- Conditions
- Friedreich's Ataxia
- Interventions
- Drug: Interferon γ-1bDrug: Placebo
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT02415127
- Locations
- 🇺🇸
University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 478
- Registration Number
- NCT02412878
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
🇺🇸Blood and Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 66
- Registration Number
- NCT02412306
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, Japan
🇯🇵Osaka City General Hospital, Osaka-shi, Osaka, Japan
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: PlaceboDrug: AMG 623
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT02411136
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Phase 3
Completed
- Conditions
- Leukemia, Acute Lymphoblastic
- Interventions
- Drug: VincrisitneDrug: Erwinia-asparaginase
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT02393859
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
Phase 3
Completed
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 158
- Registration Number
- NCT02392559
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 57
- Registration Number
- NCT02391259
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7
- Registration Number
- NCT02384317
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 851
- Registration Number
- NCT02376790
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Phase 2
Completed
- Conditions
- Unresected Stage IIIb to IVM1c Melanoma
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 112
- Registration Number
- NCT02366195
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath